Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 999-1009

  Grem, Jean L ^a   Danenberg, Kathleen D ^b   Behan, Katherine ^a   Parr, Allyson ^a   Young, Lauren ^a   Danenberg, Peter V ^b   Nguyen, Diana ^a   Drake, James ^c   Monks, Anne ^d   Allegra, Carmen J ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLOXURIDINE; FLUOROURACIL; MESSENGER RNA; PROTEIN P53; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CELL LINE; DATABASES, FACTUAL; DIHYDROURACIL DEHYDROGENASE (NADP); DNA; DRUG SCREENING ASSAYS, ANTITUMOR; FLOXURIDINE; FLUOROURACIL; HUMANS; MUTATION; NATIONAL INSTITUTES OF HEALTH (U.S.); OXIDOREDUCTASES; RNA, MESSENGER; THYMIDINE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 0034906625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
2. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen
3. The National Cancer Institute: Cancer drug discovery and development program
4. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen
5. The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets
6. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and compare algorithm
7. Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel
8. Neural computing in cancer drug development: Predicting mechanism of action
9. Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: Predicting biochemical mechanism of action
10. An information-intensive approach to the molecular pharmacology of cancer
11. Molecular targets in the National Cancer Institute drug screen
12. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen
13. Bisimidazoacridones and related compounds: New antineoplastic agents with high selectivity against colon tumors
14. Fluoropyrimidines
15. Thymidylate synthase protein expression association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma
16. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
17. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
18. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
19. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy
20. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
21. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site
22. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
23. Dihydropyrimidine dehydrogenase: A tumoral target for fluorouracil modulation
24. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
25. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
26. Isolation of fluoropyrimidine-resistant murine leukemic cell lines by one-step mutation and selection
27. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines
28. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells
29. The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracil
30. Collateral resistance of a dideoxycytidine-resistant cell line to 5-fluoro-2′-deoxyuridine
31. Differences in the kinetic properties of thymidine kinase isoenzymes in unstimulated and phytohemagglutinin-stimulated human lymphocytes
32. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS106 in 5-fluorouracil-sensitive and-resistant human cancer cell lines
33. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
34. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
35. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole
36. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line
37. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells
38. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastro-intestinal Tumor Therapy (TTD) study
39. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma
40. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol
41. Phase I trial of 5-fluorouracil and dipyridamole administered by 72-hour concurrent continuous infusion
42. A Phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with n-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma
43. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2′-deoxyuridine in the HCT-8 human carcinoma
44. Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2′-deoxyuridine
45. Transport of 5-fluorouracil and uracil into human erythrocytes
46. Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate
47. Folate-based thymidylate synthase inhibitors in cancer chemotherapy
48. Methods in analysis of apoptosis and cell necrosis
49. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
50. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
51. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate